Top Medical Searches

Charleston Laboratories, Inc. Resubmits NDA for CL-108

Jupiter, Florida ─ October 17, 2017 ─ Charleston Laboratories, Inc. announced today that it resubmitted the new drug application (NDA) for its novel investigational treatment, CL-108, for the relief of moderate to severe acute pain while… Read More..

Be Sociable, Share!
October 17th, 2017 Posted in NewDrugs
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us